​

Cellectar Biosciences (CLRB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

CLRB Stock Forecast

Cellectar Biosciences (CLRB) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 2627.27% increase from the last price of $0.44.

- $3 $6 $9 $12 $15 High: $12 Avg: $12 Low: $12 Last Closed Price: $0.44

CLRB Stock Rating

Cellectar Biosciences stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

CLRB Price Target Upside V Benchmarks

TypeNameUpside
StockCellectar Biosciences2627.27%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.44$0.44$0.44
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25112--4
May, 25211--4
Apr, 25211--4
Mar, 25211--4
Feb, 25211--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 28, 2024Jeff JonesOppenheimer$12.00$3.64229.67%2627.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 14, 2024OppenheimerOutperformOutperformhold
Mar 28, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.11$-1.22----
Avg Forecast$-2.68$-1.61$-0.70$-0.98$-0.79$-0.56
High Forecast$-2.27$-1.47$-0.64$-0.62$-0.50$-0.56
Low Forecast$-3.08$-1.74$-0.74$-1.34$-1.42$-0.56
Surprise %16.04%-24.22%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$1.75M$15.00M$92.03M$153.02M$152.06M
High Forecast-$1.75M$15.00M$92.03M$153.02M$152.06M
Low Forecast-$1.75M$15.00M$92.03M$153.02M$152.06M
Surprise %------

Net Income Forecast

$-45M $-37M $-29M $-21M $-13M $-5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-37.98M$-44.58M----
Avg Forecast$-32.71M$-19.64M$-8.43M$-11.98M$-11.73M$-6.81M
High Forecast$-27.73M$-18.02M$-7.79M$-7.58M$-6.11M$-6.81M
Low Forecast$-37.70M$-21.26M$-9.08M$-16.38M$-17.35M$-6.81M
Surprise %16.11%126.96%----

CLRB Forecast FAQ

Is Cellectar Biosciences stock a buy?

Cellectar Biosciences stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cellectar Biosciences is a favorable investment for most analysts.

What is Cellectar Biosciences's price target?

Cellectar Biosciences's price target, set by 7 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 2627.27% change from the previous closing price of $0.44.

How does Cellectar Biosciences stock forecast compare to its benchmarks?

Cellectar Biosciences's stock forecast shows a 2627.27% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Cellectar Biosciences over the past three months?

  • June 2025: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Cellectar Biosciences’s EPS forecast?

Cellectar Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.7, marking a -42.62% decrease from the reported $-1.22 in 2024. Estimates for the following years are $-0.98 in 2026, $-0.79 in 2027, and $-0.56 in 2028.

What is Cellectar Biosciences’s revenue forecast?

Cellectar Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $15M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $92.03M, followed by $153.02M for 2027, and $152.06M for 2028.

What is Cellectar Biosciences’s net income forecast?

Cellectar Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-8.435M, representing a -81.08% decrease from the reported $-44.581M in 2024. Projections indicate $-11.977M in 2026, $-11.733M in 2027, and $-6.814M in 2028.